Selection Criteria for Heart Transplantation in Patients with End-Stage Heart Failure

  • K. V. Rudenko National Amosov Institute of Cardiovascular Surgery of the National Academy of Medical Sciences of Ukraine, Kyiv, Ukraine
  • O. Yu. Dudnyk National Amosov Institute of Cardiovascular Surgery of the National Academy of Medical Sciences of Ukraine, Kyiv, Ukraine
  • M. I. Rzhanyi National Amosov Institute of Cardiovascular Surgery of the National Academy of Medical Sciences of Ukraine, Kyiv, Ukraine
Keywords: heart transplantation, indications, contraindications, listing criteria, waiting list

Abstract

Today, heart transplantation remains the gold standard of treatment for patients with end-stage heart failure (HF). As the number of donors is limited and the risk of intervention is quite high, the key to achieving optimal outcomes and reducing the incidence of complications is the proper selection of patients who meet clearly defined criteria for inclusion in the waiting list for heart transplantation. This review presents the latest knowledge on indications and contraindications for inclusion recipients in the waiting list for heart transplantation, including the latest clinical guidelines of The International Society for Heart and Lung Transplantation (ISHLT) published in 2016.

Thus, the absolute indications are dependence on intravenous inotropic and mechanical circulatory support; inoperable heart diseases or a history of volume reducing operations; refractory angina or life-threatening refractory arrhythmias despite maximal drug therapy and/or surgical correction; reduction of maximum oxygen consumption up to <12-14 ml/kg/min when performing the maximum cardiopulmonary exercise test. While including patients in the waiting list for heart transplantation, it should be noted that the low left ventricular ejection fraction <30%, a history of documented NYHA class III-IV HF, low maximum oxygen consumption as the only criterion of terminal HF and poor prognosis for annual survival in HF calculated on prognostic scales are not sufficient indications. Absolute contraindications include a systemic disease with a life expectancy of less than 2 years and irreversible pulmonary hypertension.

The current procedure for the distribution of recipients by urgency status for heart transplantation is presented according to the updated recommendations of the United Network for Organ Sharing (UNOS) published in 2018 which consists of 6 degrees, compared with the 1999 edition which contained 3 degrees.

References

  1. Joseph P, Leong D, McKee M, Anand SS, Schwalm JD, Teo K, Mente A, Yusuf S. Reducing the Global Burden of Cardiovascular Disease, Part 1: The Epidemiology and Risk Factors. Circ Res. 2017 Sep 1;121(6):677-694. https://doi.org/10.1161/CIRCRESAHA.117.308903
  2. Kovalenko VM, editor. Nastanova z kardiolohii [Cardiology Guide]. Kyiv; 2009. Ukrainian.
  3. Metra M, Ponikowski P, Dickstein K, McMurray JJ, Gavazzi A, Bergh CH, Fraser AG, Jaarsma T, Pitsis A, Mohacsi P, Böhm M, Anker S, Dargie H, Brutsaert D, Komajda M; Heart Failure Association of the European Society of Cardiology. Advanced chronic heart failure: A position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2007 Jun-Jul;9(6-7):684-694. https://doi.org/10.1016/j.ejheart.2007.04.003
  4. López-Cardoza U, Díez-López C, González-Costello J. Heart Transplant: Current Indications and Patient Selection. In: Loforte A, editor. Heart Transplantation. New York: IntechOpen; 2018. https://doi.org/10.5772/intechopen.75507.
  5. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B; EMPHASIS-HF Study Group. Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms. N Engl J Med. 2011 Jan 6;364(1):11-21. https://doi.org/10.1056/NEJMoa1009492
  6. Jhund PS, Macintyre K, Simpson CR, Lewsey JD, Stewart S, Redpath A, Chalmers JW, Capewell S, McMurray JJ. Long-Term Trends in First Hospitalization for Heart Failure and Subsequent Survival Between 1986 and 2003. Circulation. 2009 Feb 3;119(4):515-523. https://doi.org/10.1161/CIRCULATIONAHA.108.812172
  7. González-Vílchez F, Gómez-Bueno M, Almenar-Bonet L, Crespo-Leiro MG, Arizón Del Prado JM, Delgado-Jiménez J, Sousa-Casasnovas I, Brossa-Loidi V, Sobrino-Márquez JM, González-Costelo J; Spanish Heart Transplant Teams. Spanish Heart Transplant Registry. 28th Official Report of the Spanish Society of Cardiology Working Group on Heart Failure (1984-2016). Rev Esp Cardiol (Engl Ed). 2017 Dec;70(12):1098-1109. English, Spanish. https://doi.org/10.1016/j.rec.2017.10.016
  8. Mehra MR, Canter CE, Hannan MM, Semigran MJ, Uber PA, Baran DA, Danziger-Isakov L, et al. The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: A 10year update. J Heart Lung Transplant. 2016 Jan;35(1):1-23. https://doi.org/10.1016/j.healun. 2015.10.023
  9. Liu J, Yang BQ, Itoh A, Masood MF, Hartupee JC, Schilling JD. Impact of New UNOS Allocation Criteria on Heart Transplant Practices and Outcomes. Transplant Direct. 2020 Dec 15;7(1):e642. https://doi.org/10.1097/TXD.0000000000001088
Published
2021-10-27
How to Cite
Rudenko, K. V., Dudnyk, O. Y., & Rzhanyi, M. I. (2021). Selection Criteria for Heart Transplantation in Patients with End-Stage Heart Failure. Transplantation and Artificial Organs, (2 (03), 8-16. https://doi.org/10.30702/transpaorg/10_21.2710/0908-16/46.616
Section
SCIENTIFIC PUBLICATIONS